Cargando…

Outcomes and toxicities of immune checkpoint inhibitors in colorectal cancer: a real‐world retrospective analysis

Detalles Bibliográficos
Autores principales:	Zhou, Chengjing, Jiang, Ting, Li, Rongzhen, Yuan, Yan, Xie, Weihao, Huang, Xiaoxue, Wang, Qiaoxuan, Chang, Hui, Chen, Gong, Li, Yuhong, Zeng, Zhifan, Xiao, Weiwei, Gao, Yuanhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8441054/ https://www.ncbi.nlm.nih.gov/pubmed/34327863 http://dx.doi.org/10.1002/cac2.12199

Ejemplares similares

Colorectal cancer, radiotherapy and gut microbiota
por: Zhang, Shu, et al.
Publicado: (2019)

Neoadjuvant chemotherapy and radiotherapy followed by resection/ablation in stage IV rectal cancer patients with potentially resectable metastases
por: Li, Rongzhen, et al.
Publicado: (2021)

Good Tumor Response to Chemoradioimmunotherapy in dMMR/MSI-H Advanced Colorectal Cancer: A Case Series
por: Zhou, Chengjing, et al.
Publicado: (2021)

Colorectal cancer under 20 years old: a retrospective analysis from three tertiary hospitals
por: Zhou, Chengjing, et al.
Publicado: (2020)

Hematologic and lymphatic system toxicities associated with immune checkpoint inhibitors: a real-world study
por: Li, Na, et al.
Publicado: (2023)

Real-world adherence to toxicity management guidelines for immune checkpoint inhibitor-induced diabetes mellitus
por: Shen, Min, et al.
Publicado: (2023)

ypTNM category combined with AJCC tumor regression grade for screening patients with the worst prognosis after neoadjuvant chemoradiation therapy for locally advanced rectal cancer
por: Wei, Jiawang, et al.
Publicado: (2018)

Efficacy and safety of immune checkpoint inhibitors in advanced pancreatic cancer: A real world study in Chinese cohort
por: Gong, Xiaoling, et al.
Publicado: (2022)

Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma
por: Bol, Kalijn Fredrike, et al.
Publicado: (2019)

Real-world safety experience with immune checkpoint inhibitors in Saudi Arabia
por: Al Nuhait, Mohammed, et al.
Publicado: (2021)

First-line Immune Checkpoint Inhibitor Versus Immune Checkpoint Inhibitor With Chemotherapy for Cisplatin-ineligible Metastatic Urothelial Carcinoma: Evidence From a Real-world, Multicenter Analysis
por: Lin, Chang-Ting, et al.
Publicado: (2022)

Immune Checkpoint Inhibitor–Associated Tumor Lysis Syndrome: A Real-World Pharmacovigilance Study
por: Wang, Li, et al.
Publicado: (2021)

Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients
por: Machado, Marina Amaral de Ávila, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor Uptake in Real-World Patients With Malignant Pleural Mesothelioma
por: Kim, Roger Y., et al.
Publicado: (2021)

Cardiotoxicity Related to Immune Checkpoint Inhibitors: A Real-World Retrospective Analysis
por: She, Jianqing, et al.
Publicado: (2022)

Cardiotoxicity Secondary to Immune Checkpoint Inhibitors in the Elderly: Safety in Real-World Data
por: Toribio-García, Irene, et al.
Publicado: (2023)

Immune checkpoint inhibitor plus tyrosine kinase inhibitor for unresectable hepatocellular carcinoma in the real world
por: Xie, Diyang, et al.
Publicado: (2021)

Real-world outcome of immune checkpoint inhibitors for advanced hepatocellular carcinoma with macrovascular tumor thrombosis
por: Tsai, Hong-Ming, et al.
Publicado: (2021)

Cardiovascular toxicity profiles of immune checkpoint inhibitors with or without angiogenesis inhibitors: a real-world pharmacovigilance analysis based on the FAERS database from 2014 to 2022
por: Wang, Yanfeng, et al.
Publicado: (2023)

Management of Immune Checkpoint Inhibitor Toxicities
por: Durrechou, Quentin, et al.
Publicado: (2020)

Toxicities associated with checkpoint inhibitors—an overview
por: Spiers, Laura, et al.
Publicado: (2019)

Real-world outcomes of regorafenib combined with immune checkpoint inhibitors in patients with advanced or metastatic microsatellite stable colorectal cancer: A multicenter study
por: Yang, Kaili, et al.
Publicado: (2021)

Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system
por: Zhai, Yinghong, et al.
Publicado: (2019)

Respiratory system toxicity induced by immune checkpoint inhibitors: A real-world study based on the FDA adverse event reporting system database
por: Cui, Chanjuan, et al.
Publicado: (2022)

The Prevalence and Patterns of Toxicity With Immune Checkpoint Inhibitors in Solid Tumors: A Real-World Experience From a Tertiary Care Center in Oman
por: Salman, Bushra, et al.
Publicado: (2023)

Real-World Outcomes for Patients Treated With Immune Checkpoint Inhibitors in the Veterans Affairs System
por: La, Jennifer, et al.
Publicado: (2020)

A real‐world data of Immune checkpoint inhibitors in solid tumors from India
por: Noronha, Vanita, et al.
Publicado: (2021)

Intrinsic Differences in Immune Checkpoint Inhibitor-Induced Myocarditis: A Retrospective Analysis of Real World Data
por: Lei, Yanna, et al.
Publicado: (2022)

Real-World Data of Different Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer in China
por: Miao, Kang, et al.
Publicado: (2022)

Nomogram to Predict Distant Metastasis Probability for Pathological Complete Response Rectal Cancer Patients After Neoadjuvant Chemoradiotherapy
por: Jiang, Ting, et al.
Publicado: (2021)

Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies
por: Hradska, Katarina, et al.
Publicado: (2021)

Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung
por: Dudnik, Elizabeth, et al.
Publicado: (2021)

Real-world insights on preferred treatments for steroid-refractory immune checkpoint inhibitor-induced pneumonitis
por: Gatti-Mays, Margaret, et al.
Publicado: (2021)

Real-World Outcomes and Clinical Predictors of Immune Checkpoint Inhibitor Monotherapy in Advanced Lung Cancer
por: Zhang, Shijia, et al.
Publicado: (2021)

Inflammation promotes resistance to immune checkpoint inhibitors in high microsatellite instability colorectal cancer
por: Sui, Qiaoqi, et al.
Publicado: (2022)

Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma
por: Sun, Meiling, et al.
Publicado: (2022)

Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers
por: Li, Haoran, et al.
Publicado: (2022)

Concomitant Medication Effects on Immune Checkpoint Inhibitor Efficacy and Toxicity
por: Sieber, Brendan, et al.
Publicado: (2022)

Safety and Efficacy of Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma and End-Stage Renal Disease: Experiences From Real-World Practice
por: Kuo, Ming-Chun, et al.
Publicado: (2020)

Immune-Checkpoint Inhibitors for Malignant Pleural Mesothelioma: A French, Multicenter, Retrospective Real-World Study
por: Assié, Jean-Baptiste, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0ak7274bkmlatsi6k9b77opv1c